{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Taya M"],"funding":["Cancer Prevention Research Institute of Texas Recruitment of Established Investigators Award","Mayo Clinic SPORE in Ovarian Cancer Developmental Research Program, Pilot Study Award","National Cancer Institute","NCI NIH HHS","The University of Chicago Women's Board","The University of Chicago Comprehensive Cancer Center","The University of Chicago Women’s Board","2017 Conquer Cancer Foundation/ASCO Young Investigator Award"],"pagination":["e4"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11790989"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["36(1)"],"pubmed_abstract":["<h4>Objective</h4>In ovarian cancer (OvCa), tumor cell high glucocorticoid receptor (GR) has been associated with poor patient prognosis. In vitro, GR activation inhibits chemotherapy-induced OvCa cell death in association with transcriptional upregulation of genes encoding anti-apoptotic proteins. A recent randomized phase II study demonstrated improvement in progression-free survival (PFS) for heavily pre-treated OvCa patients randomized to receive therapy with a selective GR modulator (SGRM) plus chemotherapy compared to chemotherapy alone. We hypothesized that SGRM therapy would improve carboplatin response in OvCa patient-derived xenograft (PDX).<h4>Methods</h4>Six high-grade serous (HGS) OvCa PDX models expressing GR mRNA (<i>NR3C1</i>) and protein were treated with chemotherapy +/- "],"journal":["Journal of gynecologic oncology"],"pubmed_title":["Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models."],"pmcid":["PMC11790989"],"funding_grant_id":["P30 CA 14599","NIH1R21CA223426","P50 CA136393","RR1900371","5P50CA136393-09","P30 CA142543","P30 CA014599","R21 CA223426"],"pubmed_authors":["Taya M","Oberg AL","Heinzen EP","Chen H","Hou X","Fleming GF","Veneris JT","Maurer MJ","Larson MC","Kazi N","Conzen SD","Lastra R","Weroha SJ"],"additional_accession":[]},"is_claimable":false,"name":"Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models.","description":"<h4>Objective</h4>In ovarian cancer (OvCa), tumor cell high glucocorticoid receptor (GR) has been associated with poor patient prognosis. In vitro, GR activation inhibits chemotherapy-induced OvCa cell death in association with transcriptional upregulation of genes encoding anti-apoptotic proteins. A recent randomized phase II study demonstrated improvement in progression-free survival (PFS) for heavily pre-treated OvCa patients randomized to receive therapy with a selective GR modulator (SGRM) plus chemotherapy compared to chemotherapy alone. We hypothesized that SGRM therapy would improve carboplatin response in OvCa patient-derived xenograft (PDX).<h4>Methods</h4>Six high-grade serous (HGS) OvCa PDX models expressing GR mRNA (<i>NR3C1</i>) and protein were treated with chemotherapy +/- ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2026-04-14T03:26:49.684Z","creation":"2025-04-19T16:22:33.915Z"},"accession":"S-EPMC11790989","cross_references":{"pubmed":["38909640"],"doi":["10.3802/jgo.2025.36.e4"]}}